POSTER: ALL-022 Assessment of Molecular Response to Tyrosine Kinase Inhibitors in Tunisian Patients With Ph+ Acute Lymphoblastic Leukemia

CML-674 Molecular Screening of Tyrosine Kinase Inhibitor Resistance in Tunisian Patients With Chronic Myeloid Leukemia

Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors

Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia

Background: The fms-like tyrosine kinase 3 (FLT3) gene belong to the class III receptor tyrosine kin

ALL-BFM 95 Treatment in Turkish Children with Acute Lymphoblastic Leukemia—Experience of a Single Center

Molecular Profiling of Kenyan Acute Myeloid Leukemia Patients

Acute myeloid leukemia (AML) is an infrequent disease, and it is associated with high morbidity and

hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia

International audience Imatinib mesylate (IM) is considered as a highly effective the